chronic cisplatin induced nephropathy

Cisplatin is the most widely used agent in the chemotherapy of cancer. The
chief limit to efficacy is its toxicity (nephrotoxicity, neurotoxicity and
ototoxicity). Cisplatin-induced nephropathy or chronic kidney injury can
present as a decreased glomerular filtration rate (GFR), and tubulopathy
leading to the loss of electrolytes such as magnesium. Most reports have
studied the short term effects of cisplatin therapy only (acute kidney injury
and initial hypomagnesemia). The long term nephrotoxic effects of cisplatin
however could be very relevant as chronic hypophosphatemia, hypomagnesemia and
a decreased GFR result in a decreased quality of life and increased mortality.
The timely diagnosis and therefore treatment of chronic cisplatin nephrotoxicty
could improve quality of life, morbidity and mortality of patients who have
been treated with cisplatin.

to determine the prevalence and significance of chronic nephrotoxic effects of
cisplatin therapy by 1) identifying patients with chronic cisplatin
nephrotoxicity and 2) reviewing their QoL. Eventually, this could improve care
in these patients

cross-sectional study in which all patients who received cisplatin therapy more
than one year ago and visit the outpatient oncology clinic will be included.
Blood and urine investigations will be performed and a quality of life
questionnaire is taken after the patient has given his/her informed consent.

There is only a small risk accompanying the withdrawal of blood in those
patients in whom otherwise blood was not taken.